share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/20 02:16

Moomoo AI 已提取核心訊息

FOXO Technologies reported Q3 2024 revenues of $1.2 million, a significant increase from $10,000 in Q3 2023, primarily driven by its newly acquired healthcare segment. The company's net loss attributable to FOXO improved to $1.9 million compared to $3.7 million in the prior year period, while operating expenses decreased 37% to $2.2 million.The company completed strategic acquisitions of Myrtle Recovery Centers in June 2024 and Rennova Community Health in September 2024, establishing its healthcare segment which contributed $1.2 million in revenue. The Labs and Life segment continued development of epigenetic biomarker technology while reducing operating costs through headcount reductions and other efficiency measures.Management expressed concerns about liquidity, with only $34,000 in cash as of September 30, 2024. The company is pursuing additional funding through equity/debt financing and strategic acquisitions to fund operations, which are expected to be sustainable through Q2 2025 following the RCHI acquisition. FOXO also faces challenges with NYSE American listing compliance and defaulted Senior PIK Notes.
FOXO Technologies reported Q3 2024 revenues of $1.2 million, a significant increase from $10,000 in Q3 2023, primarily driven by its newly acquired healthcare segment. The company's net loss attributable to FOXO improved to $1.9 million compared to $3.7 million in the prior year period, while operating expenses decreased 37% to $2.2 million.The company completed strategic acquisitions of Myrtle Recovery Centers in June 2024 and Rennova Community Health in September 2024, establishing its healthcare segment which contributed $1.2 million in revenue. The Labs and Life segment continued development of epigenetic biomarker technology while reducing operating costs through headcount reductions and other efficiency measures.Management expressed concerns about liquidity, with only $34,000 in cash as of September 30, 2024. The company is pursuing additional funding through equity/debt financing and strategic acquisitions to fund operations, which are expected to be sustainable through Q2 2025 following the RCHI acquisition. FOXO also faces challenges with NYSE American listing compliance and defaulted Senior PIK Notes.
FOXO科技在2024年第三季度報告的營業收入爲120萬美元,相較於2023年第三季度的10,000美元有顯著增長,這主要得益於其新收購的醫療保健部門。公司的淨虧損歸屬於FOXO從去年同期的370萬美元改善至190萬美元,而營業費用減少了37%,降至220萬美元。該公司在2024年6月完成了對Myrtle Recovery Centers的戰略收購,並在2024年9月收購了Rennova社區健康,建立了其醫療保健部門,該部門爲公司貢獻了120萬美元的營業收入。實驗室及生命部門繼續開發表觀遺傳生物標誌物技術,同時通過裁員和其他效率措施降低營業費用。管理層對流動性表示擔憂,截至2024年9月30日,公司的現金僅爲34,000美元。公司正在通過股權/債務融資和戰略收購尋求額外資金,以支持運營,預計在2025年第二季度將是可持續的,此次爲RCHI收購之後。FOXO還面臨紐約證券交易所美國上市合規和違約高級PIK票據的挑戰。
FOXO科技在2024年第三季度報告的營業收入爲120萬美元,相較於2023年第三季度的10,000美元有顯著增長,這主要得益於其新收購的醫療保健部門。公司的淨虧損歸屬於FOXO從去年同期的370萬美元改善至190萬美元,而營業費用減少了37%,降至220萬美元。該公司在2024年6月完成了對Myrtle Recovery Centers的戰略收購,並在2024年9月收購了Rennova社區健康,建立了其醫療保健部門,該部門爲公司貢獻了120萬美元的營業收入。實驗室及生命部門繼續開發表觀遺傳生物標誌物技術,同時通過裁員和其他效率措施降低營業費用。管理層對流動性表示擔憂,截至2024年9月30日,公司的現金僅爲34,000美元。公司正在通過股權/債務融資和戰略收購尋求額外資金,以支持運營,預計在2025年第二季度將是可持續的,此次爲RCHI收購之後。FOXO還面臨紐約證券交易所美國上市合規和違約高級PIK票據的挑戰。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息